Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 2/20 | 0.68 |
| ▸ | GALNT2 | Q10471 | 2/20 | 0.68 |
| ▸ | GALNT1 | Q10472 | 1/20 | 0.68 |
| ▸ | GALNT3 | Q14435 | 1/20 | 0.68 |
| ▸ | GALNT10 | Q86SR1 | 1/20 | 0.68 |
| ▸ | GALNT13 | Q8IUC8 | 1/20 | 0.68 |
| ▸ | GALNT6 | Q8NCL4 | 1/20 | 0.68 |
| ▸ | GALNT14 | Q96FL9 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.66 |
| ▸ | MET | P08581 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | BLM | P54132 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | PLK4 | O00444 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2357304 | 1.00 | PKLR (0.68) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL29827270 | 1.00 | PKLR (0.68) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL30301204 | 0.82 | MAOA (0.59) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL21517158 | 0.82 | ATP1A1 (0.61) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL18602000 | 0.81 | PKLR (0.79) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL7980209 | 0.81 | PKLR (1.00) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL29370098 | 0.81 | PKLR (1.00) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| SCHEMBL14047691 | 0.80 | PKLR (0.55) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| Ellagic Acid SCHEMBL29439360 | 0.80 | KDM4E (1.00) | PKLRGALNT2GALNT1GALNT3GALNT10 | |
| Ellagic Acid SCHEMBL1645767 | 0.80 | KDM4E (1.00) | PKLRGALNT2GALNT1GALNT3GALNT10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056946-A | Rose extract and preparation method and application thereof | 遵义医科大学 | 2026-05-19 | — | — | CN | claimed |
| US-20250327022-A1 | MICROBIAL METHOD FOR REPRODUCING THE HUMAN UROLITHIN METABOTYPES IN VITRO AND IN VIVO | CONSEJO SUPERIOR INVESTIGACION (ES) | 2025-10-23 | — | — | US | claimed |
| US-20250302746-A1 | METHOD FOR PRODUCING EMULSIFIED COMPOSITION | DAICEL CORPORATION (JP) | 2025-10-02 | — | — | US | claimed |
| CN-120022204-A | Preparation method of water-soluble urolithin compound powder | 广州田佳生物科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-118169296-B | Ellagic acid and metabolite detection method thereof | 广东海洋大学 | 2025-02-14 | — | — | CN | claimed |
| US-12006524-B2 | Method for producing urolithins | DAICEL CORPORATION (JP) | 2024-06-11 | — | — | US | claimed |
| WO-2024083910-A1 | MICROBIAL METHOD FOR REPRODUCING THE HUMAN UROLITHIN METABOTYPES IN VITRO AND IN VIVO | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2024-04-25 | — | — | WO | claimed |
| EP-4356757-A1 | MICROBIAL METHOD FOR REPRODUCING THE HUMAN UROLITHIN METABOTYPES IN VITRO AND IN VIVO | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2024-04-24 | — | — | EP | claimed |
| CN-110225978-B | Method for producing urolithin | 株式会社大赛璐 | 2024-04-02 | — | — | CN | claimed |
| WO-2023199908-A1 | METHOD FOR PRODUCING EMULSIFIED COMPOSITION | 株式会社ダイセル | 2023-10-19 | — | — | WO | claimed |
| US-20230323414-A1 | ENZYME DEHYDROXYLATING HYDROXYL GROUP AT 9-POSITION OF UROLITHIN COMPOUND | DAICEL CORPORATION (JP) | 2023-10-12 | — | — | US | claimed |
| CN-116642988-A | Method for measuring content of multiple components in myrobalan and constructing characteristic fingerprint | 天津中医药大学 | 2023-08-25 | — | — | CN | claimed |
| EP-4206326-A1 | ENZYME DEHYDROXYLATING HYDROXYL GROUP AT 9-POSITION OF UROLITHIN COMPOUND | Daicel Corporation (JP) | 2023-07-05 | — | — | EP | claimed |
| EP-4153306-A1 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS | Ilera Derm LLC (US) | 2023-03-29 | — | — | EP | claimed |
| US-20220267741-A1 | ENZYME CAPABLE OF DEHYDROXYLATING HYDROXYL GROUP IN UROLITHIN COMPOUND | DAICEL CORPORATION (JP) | 2022-08-25 | — | — | US | claimed |
| EP-3561067-B1 | METHOD FOR PRODUCING UROLITHINS | DAICEL CORP (JP) | 2022-08-03 | — | — | EP | claimed |
| EP-4006163-A1 | ENZYME CAPABLE OF DEHYDROXYLATING HYDROXYL GROUP IN UROLITHIN COMPOUND | Daicel Corporation (JP) | 2022-06-01 | — | — | EP | claimed |
| EP-3756664-B1 | OSTEOCLAST DIFFERENTIATION INHIBITOR CONTAINING UROLITHIN | DAICEL CORP (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-20220105117-A1 | COMPOSITIONS COMPRISING NICOTINAMIDE RIBOSIDE AND A UROLITHIN | AMAZENTIS SA (CH) | 2022-04-07 | — | — | US | disclosed |
| US-20220073488-A1 | COMPOSITIONS COMPRISING AN UROLITHIN COMPOUND | AMAZENTIS SA (CH) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302746-A1 | METHOD FOR PRODUCING EMULSIFIED COMPOSITION | LIPA, MGLL, LCAT | PKLR 2763/4885GALNT2 509/4885GALNT1 784/4885 |
| US-20250327022-A1 | MICROBIAL METHOD FOR REPRODUCING THE HUMAN UROLITHIN METABOTYPES IN VITRO AND IN VIVO | LGALS9, LGALS4, GALE | PKLR 3231/4885GALNT2 116/4885GALNT1 143/4885 |
| US-20220105117-A1 | COMPOSITIONS COMPRISING NICOTINAMIDE RIBOSIDE AND A UROLITHIN | NNT, UQCRC1, UQCRC2 | PKLR 2582/4885GALNT2 313/4885GALNT1 317/4885 |
| US-20220073488-A1 | COMPOSITIONS COMPRISING AN UROLITHIN COMPOUND | PYGM, UTS2R, MUSK | PKLR 1846/4885GALNT2 148/4885GALNT1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.